Khan A, Iqbal A, Muhammad A, Mazhar F, Lodhi M, Ahmed K
Cureus. 2023; 15(4):e37650.
PMID: 37200652
PMC: 10188129.
DOI: 10.7759/cureus.37650.
Shi Z, Zhang J, Tian L, Xin L, Liang C, Ren X
Molecules. 2023; 28(4).
PMID: 36838752
PMC: 9962477.
DOI: 10.3390/molecules28041762.
Zhao B, Yu X, Chen R, Zheng R
Infect Drug Resist. 2020; 13:2099-2104.
PMID: 32669862
PMC: 7337426.
DOI: 10.2147/IDR.S248092.
Chang S, Lee H, Lai C, Tang H
Infect Drug Resist. 2019; 12:433-438.
PMID: 30863126
PMC: 6388749.
DOI: 10.2147/IDR.S193233.
Li Z, Liu Y, Wang R, Li A
World J Microbiol Biotechnol. 2014; 30(11):2927-32.
PMID: 25129332
DOI: 10.1007/s11274-014-1720-2.
Nemonoxacin: first global approval.
Poole R
Drugs. 2014; 74(12):1445-53.
PMID: 25079302
DOI: 10.1007/s40265-014-0270-0.
Review of nemonoxacin with special focus on clinical development.
Qin X, Huang H
Drug Des Devel Ther. 2014; 8:765-74.
PMID: 25045247
PMC: 4094567.
DOI: 10.2147/DDDT.S63581.
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
Chotikanatis K, Kohlhoff S, Hammerschlag M
Antimicrob Agents Chemother. 2013; 58(3):1800-1.
PMID: 24366753
PMC: 3957896.
DOI: 10.1128/AAC.02263-13.
Direct observation therapy with appropriate treatment regimens was associated with a decline in second-line drug-resistant tuberculosis in Taiwan.
Chien J, Tsou C, Chien S, Yu C, Hsueh P
Eur J Clin Microbiol Infect Dis. 2013; 33(6):941-8.
PMID: 24338066
DOI: 10.1007/s10096-013-2030-6.
Clinical effects of gemifloxacin on the delay of tuberculosis treatment.
Kim S, Yim J, Park J, Park S, Heo E, Lee C
J Korean Med Sci. 2013; 28(3):378-82.
PMID: 23486643
PMC: 3594600.
DOI: 10.3346/jkms.2013.28.3.378.
Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.
El Sahly H, Teeter L, Jost Jr K, Dunbar D, Lew J, Graviss E
J Clin Microbiol. 2011; 49(8):2942-5.
PMID: 21653760
PMC: 3147712.
DOI: 10.1128/JCM.00231-11.
Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
Lai C, Liu W, Ko W, Chen Y, Tan H, Huang Y
Antimicrob Agents Chemother. 2011; 55(5):2084-91.
PMID: 21343461
PMC: 3088233.
DOI: 10.1128/AAC.01808-10.
Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.
van Rensburg D, Perng R, Mitha I, Bester A, Kasumba J, Wu R
Antimicrob Agents Chemother. 2010; 54(10):4098-106.
PMID: 20660689
PMC: 2944601.
DOI: 10.1128/AAC.00295-10.
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Yang J, Lee P, Hsueh P
Eur J Clin Microbiol Infect Dis. 2010; 29(11):1369-75.
PMID: 20658256
DOI: 10.1007/s10096-010-1009-9.
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Adam H, Laing N, King C, Lulashnyk B, Hoban D, Zhanel G
Antimicrob Agents Chemother. 2009; 53(11):4915-20.
PMID: 19738018
PMC: 2772340.
DOI: 10.1128/AAC.00078-09.
